The purpose of this study is to see what effects sacral neuromodulation has on bladder function and quality of life in patients with acute spinal cord injury. Within 12-weeks of injury, participants will either receive an implanted nerve stimulator (like a pace-maker for the bladder) or standard care for neurogenic bladder. Patients will be assigned to one of these groups at random and followed for one year. The hypothesis is that early stimulation of the nerves will help prevent the development of neurogenic bladder.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
5
Bilateral s S3 sacral neuromodulation delivered via the PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
Rancho Los Amigos National Rehabilitation Center
Downey, California, United States
University of Utah
Salt Lake City, Utah, United States
Maximum Cystometric Capacity
Maximum bladder capacity as measured by urodynamic study at 12 months
Time frame: 12 months
Quality of Life Differences Measured by Mean SCI-QoL
Participant-reported quality of life as assessed by the Spinal Cord Injury - Quality of Life (SCI-QOL) bladder question banks at 12 months. Scores range from 64-320 with a lower score indicating greater satisfaction with quality of life.
Time frame: 12 months
Number of Urinary Tract Infections Requiring Antibiotics
Time frame: from enrollment through the end of follow-up at 12 months
Maximum Cystometric Capacity at 3 Months
Maximum bladder capacity as measured by urodynamic study at 3 months
Time frame: 3 months
Bladder Compliance
Bladder compliance as measured by urodynamic study (UDS) at 3 and 12 months.
Time frame: 3, 12 months
Presence of Detrusor Overactivity
Presence of detrusor overactivity as evaluated by urodynamic study (UDS) at 3 and 12 months.
Time frame: 3, 12 months
Volume at First Detrusor Contraction
Bladder volume at first detrusor contraction as measured by urodynamic study (UDS) at 3 and 12 months.
Time frame: 3, 12 months
Pressure at First Detrusor Contraction
Bladder pressure at first detrusor contraction as measured by urodynamic study (UDS) at 3 and 12 months.
Time frame: 3, 12 months
Daily Number of Catheterizations
Daily number of catheterizations as reported in the participant diary.
Time frame: 3, 6, 9, 12 months
Average Catheterization Volume
Average catheterization volume as determined by participant diary.
Time frame: 3, 6, 9, 12 months
Urinary Incontinence Episodes Per Day
Urinary incontinence episodes per day as determined by participant diary.
Time frame: 3, 6, 9, 12 months
24 Hour Pad Weight Test
24 hour pad weight as determined by participant diary.
Time frame: 3, 6, 9, 12 months
Development of Hydronephrosis
Development of hydronephrosis during the study period as determined by ultrasound at 12 months.
Time frame: 12 months
Need for Anticholinergic Medication
Time frame: from enrollment through the end of follow-up at 12 months
Need for Onabotulinum Toxin A Injection
Time frame: from enrollment through the end of follow-up at 12 months
Need for Device Revision
Time frame: from implant through the end of follow-up at 12 months
Device Explanation
Time frame: from implant through the end of follow-up at 12 months
Hospitalizations
Time frame: from enrollment through the end of follow-up at 12 months
Urologic Related Surgeries
Time frame: from enrollment through the end of follow-up at 12 months
Death
Time frame: from enrollment through the end of follow-up at 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.